Lenvaxen 4 mg (Lenvatinib)

Lenvaxen 4 mg (Lenvatinib)

Manufactured By
Everest Pharmaceuticals Ltd.

COMPOSITION
LENVAXEN 4 capsules: Each capsule contains Lenvatinib Mesylate INN equivalent to Lenvatinib 4 mg.

LENVAXEN 10 capsules Each capsule conlains Lenvatinib Mesylate INN equivalent to Lenvatinib 10 mg.

INDICATIONS AND USAGE
Lenvatinib is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvatinib is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

DOSAGE AND ADMINISTRATION
Recommended Dosage for Differentiated Thyroid Cancer (DTC)
The recommended dosage of lenvatinib is 24 mg orally once daily until disease progression or until unacceptable toxicity.

Recommended Dosage for Renal Cell Carcinoma (RCC) The recommended dosage of lenvatinib is 18 mg in combination wilh 5 mg everolimus orally once daily until disease progression or until unacceptable toxicity.

Refer to everolimus prescribing information for recommended everolimus dosing information.